Related Experiment Videos
Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse
R K Akkina1, J D Rosenblatt, A G Campbell
1Department of Medicine, UCLA School of Medicine 90024-1678.
Blood
|September 1, 1994
Summary
This study introduces a SCID-hu mouse model for testing gene therapy in human T-lymphocytes. The model successfully reconstitutes the T-lymphoid compartment, offering a new way to study treatments for T-lymphocyte disorders like AIDS.
Area of Science:
- * Immunology
- * Molecular Biology
- * Hematology
Background:
- * Gene therapy for T-lymphocyte disorders requires an effective in vivo system for reconstituting the T-lymphoid compartment.
- * Current methods for gene therapy testing are limited in their ability to model human T-lymphopoiesis in vivo.
- * The development of a suitable animal model is crucial for advancing gene therapy for conditions like acquired immunodeficiency syndrome (AIDS).
Purpose of the Study:
- * To establish and validate an in vivo model using SCID-hu mice for preclinical gene therapy testing.
- * To demonstrate the engraftment and reconstitution of human T-lymphoid compartments by genetically modified hematopoietic stem cells.
- * To assess the feasibility of using this model for evaluating gene therapeutic reagents targeting T-lymphoid cells, including those relevant to AIDS.
Main Methods:
- * Human CD34+ hematopoietic progenitor cells were transduced in vitro with a retroviral vector encoding the neomycin resistance gene (neoR).
- * These transduced cells were engrafted into SCID-hu mice, which possess human thymus implants.
- * The reconstitution of lymphoid compartments and expression of the neoR gene in thymocytes were analyzed.
Main Results:
- * As few as 5 x 10(4) transduced CD34+ cells successfully engrafted and reconstituted the lymphoid compartments of the human thymus implant.
- * The neoR gene was expressed at low levels in human thymocytes.
- * No apparent adverse effects on thymocyte differentiation were observed due to vector transduction.
Conclusions:
- * The SCID-hu mouse model represents the first in vivo system demonstrating human thymopoiesis following exogenous vector transduction.
- * This model provides a valuable platform for the preclinical evaluation of gene therapeutic strategies for T-lymphoid lineage cells.
- * The model's utility is highlighted by its potential to assess gene therapies for AIDS, given that human immunodeficiency virus type 1 infection leads to thymocyte depletion in SCID-hu mice.